CA2934979C - Inhibition ciblee de facteur de croissance de transformation beta (tgf?) - Google Patents

Inhibition ciblee de facteur de croissance de transformation beta (tgf?)

Info

Publication number
CA2934979C
CA2934979C CA2934979A CA2934979A CA2934979C CA 2934979 C CA2934979 C CA 2934979C CA 2934979 A CA2934979 A CA 2934979A CA 2934979 A CA2934979 A CA 2934979A CA 2934979 C CA2934979 C CA 2934979C
Authority
CA
Canada
Prior art keywords
antibody
protein
tgfp
amino acid
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2934979A
Other languages
English (en)
Other versions
CA2934979A1 (fr
Inventor
Kin-Ming Lo
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority claimed from PCT/EP2015/052781 external-priority patent/WO2015118175A2/fr
Publication of CA2934979A1 publication Critical patent/CA2934979A1/fr
Application granted granted Critical
Publication of CA2934979C publication Critical patent/CA2934979C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

D'une manière générale, la présente invention concerne des molécules bifonctionnelles comportant (a) le récepteur de type II de TGFß ou un fragment de celui-ci capable de se lier à TGFß et (b) un anticorps, ou fragment de liaison à l'antigène de celui-ci, qui se lie à une protéine de point de contrôle immunitaire, tel que le ligand de mort programmée 1 (PD-L1), les utilisations de ces molécules (par exemple, pour traiter le cancer), ainsi que des procédés de fabrication de telles molécules.
CA2934979A 2014-02-10 2015-02-10 Inhibition ciblee de facteur de croissance de transformation beta (tgf?) Active CA2934979C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461938048P 2014-02-10 2014-02-10
US61/938,048 2014-02-10
PCT/EP2015/052781 WO2015118175A2 (fr) 2014-02-10 2015-02-10 Inhibition ciblee de facteur de croissance de transformation bêta (tgfβ)

Publications (2)

Publication Number Publication Date
CA2934979A1 CA2934979A1 (fr) 2015-08-13
CA2934979C true CA2934979C (fr) 2025-09-16

Family

ID=

Similar Documents

Publication Publication Date Title
US20230056881A1 (en) TARGETED TGFß INHIBITION
US20220017621A1 (en) Combination Therapy for Cancer
US20190330375A1 (en) Dosing regimens and dosage forms for targeted tgf-b inhibition
CA2934979C (fr) Inhibition ciblee de facteur de croissance de transformation beta (tgf?)
HK40064486A (en) TARGETED TGFβ INHIBITION
EP4549466A1 (fr) Développement et utilisation d'un nouvel inhibiteur de tumeur multispécifique
HK1231904B (en) Targeted tgf beta inhibition
HK1231904A1 (en) Targeted tgf beta inhibition
HK40078517B (zh) 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体